Phosphatidylserine (PS) is a phospholipid that is a critical structural component of the inner leaflet of the neuronal cell membrane — the side of the membrane that faces the cytoplasm. It is not merely a structural lipid, however: phosphatidylserine serves as a functional cofactor for numerous signalling proteins that depend on its negative charge for their membrane localisation, including protein kinase C (PKC), the Ras family of GTPases, and the Akt/PKB survival pathway. In the brain, these signalling functions translate into effects on memory consolidation, attention, and the neuronal response to growth factors and neurotransmitters.
The Asymmetric Membrane Distribution and Its Significance
In healthy neurons, phosphatidylserine is almost exclusively localised to the inner leaflet of the neuronal membrane — the outer leaflet contains predominantly phosphatidylcholine and sphingomyelin. This asymmetric distribution is maintained by the ATP-dependent enzyme phosphatidylserine synthase, which actively transports PS to the inner leaflet. In apoptosis (programmed cell death), this asymmetry is lost — PS appears on the outer leaflet, where it serves as a signal for phagocytes to engulf and remove the dying cell. This means that factors that disrupt PS asymmetry can trigger inappropriate apoptosis, a phenomenon that is thought to contribute to neurodegeneration.
In Alzheimer’s disease and normal cognitive ageing, the PS content of neuronal membranes declines, and this decline correlates with the loss of membrane fluidity and the impairment of the signalling functions that depend on PS. By supplementing with PS, it may be possible to restore membrane PS content, improve membrane fluidity, and support the signalling functions that are compromised by age-related PS depletion. This is the mechanistic rationale for PS supplementation in cognitive decline.
Clinical Evidence in Age-Related Cognitive Decline
The clinical evidence for phosphatidylserine in age-related cognitive decline and Alzheimer’s disease is mixed but intriguing. The most robust data come from studies in people with age-associated memory impairment (AAMI) — otherwise healthy older adults who are experiencing the normal memory lapses of ageing rather than a diagnosable dementia. In this population, multiple double-blind RCTs have shown that phosphatidylserine at 300mg daily improves memory on standard tests (the Buschke Selective Reminding Test, the Wechsler Memory Scale) compared to placebo, with improvements that are statistically significant and clinically meaningful for everyday function.
In Alzheimer’s disease specifically, the evidence is weaker. Early studies showed promising results, but more recent trials with better methodology have failed to replicate these effects. The current consensus in the literature is that PS is most likely to be effective in the earlier stages of cognitive decline — AAMI and mild cognitive impairment (MCI) — rather than in established Alzheimer’s disease, where the neurodegenerative process is too advanced to be significantly modified by a single phospholipid intervention.
PS for Athletic Performance and Cortisol Management
One of the more unexpected applications of phosphatidylserine is in the management of exercise-induced stress. Intense physical training elevates cortisol levels, and chronically elevated cortisol (as occurs in overtraining syndrome) produces muscle catabolism, immunosuppression, and adverse effects on mood and cognition. Phosphatidylserine at 600-900mg daily has been shown in multiple studies to blunt the cortisol response to intense exercise — a 300mg daily dose reduced the cortisol response to endurance exercise by approximately 30% compared to placebo in a double-blind RCT in 10 endurance athletes.
This cortisol-blunting effect also has implications for mood and cognitive function under stress: elevated cortisol impairs memory and attention (particularly working memory), and reducing the cortisol response to stress may therefore preserve cognitive function in high-stress environments. A study in 48 healthy adults found that phosphatidylserine at 300mg daily improved mood and reduced the cortisol response to a laboratory stress protocol compared to placebo — suggesting that the cognitive effects of PS under stress may be mediated by the cortisol reduction rather than a direct nootropic mechanism.
Dosing, Sources, and Safety
The evidence-based dose for cognitive applications is 300mg daily of phosphatidylserine, typically divided into three doses of 100mg each for better tolerability. PS from bovine cortex (bovine phosphatidylserine) has been the traditional source, but due to concerns about contamination of animal products with prion diseases, most PS supplements are now derived from soy lecithin (soy phosphatidylserine). There is some debate in the literature about whether soy-derived PS is as effective as bovine PS — the phospholipid head group (serine) is the same regardless of source, but the fatty acid tails may differ, which could affect membrane incorporation. For now, both forms are considered acceptable.
PS is generally well-tolerated with occasional mild GI discomfort at higher doses. It has no significant drug interactions and is safe for long-term use. The main contraindication is anticoagulant use (warfarin, clopidogrel) — PS has mild antiplatelet effects at high doses that may potentiate anticoagulant action.
A quality supplement routine can make a real difference to your results.
Leave a Reply